1
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      Mechanically ventilated COVID-19 patients failed to meet the criteria for the Berlin definition of ARDS

      letter

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Dear Editor, Using a consensus process, a panel of experts convened in 2011 have simplified and clarified the definition of acute respiratory distress syndrome (ARDS) and gave birth to the so called, Berlin definition of ARDS [1]. The Berlin definition was developed to achieve a more accurate definition and to better match clinical outcomes to severity of illness categories. It provided validated support for three strata of initial arterial hypoxaemia (PaO2/FiO2 categories of ≤ 100, 101–200, and 201–300 mm Hg), which correlated with mortality (45%, 32%, and 27%, respectively) [1]. Now, in 2020–21, critically ill COVID-19 patients presented typical morphological hallmarks of ARDS with lung edema, inflammation, and alveolar hemorrhage (i.e., diffuse alveolar damage) [2]. They were classified as ARDS, because the lung injury was due to an acute lung infection responsive of bilateral infiltrates on chest imaging and was responsive to arterial hypoxaemia despite mechanical ventilation with positive end-expiratory pressure and without cardiac failure explaining the respiratory failure. More than 3000 articles matched the keywords “COVID-19” and “ARDS” in 2020. However, we questioned whether ventilated COVID-19 patients meet the Berlin definition of ARDS because of long latency periods between symptom onset and respiratory failure (should be 1 week or less in the definition of ARDS). To test this assumption, we reported the time from symptoms onset to hospitalization, ICU admission and initiation of the mechanical ventilation in critically ill patients due to community-acquired SARS-CoV-2 infection. In this single-center study (prospective recording from 2020-03-14 to 2020-04-12), we included critically ill patients due to community-acquired SARS-CoV-2 infection and receiving mechanical ventilation with partial pressure of arterial oxygen to fraction of inspired oxygen (PaO2/FiO2) of 300 mm Hg or less (with positive end-expiratory pressure of 5 cm H2O or more), with bilateral infiltrates on chest imaging and without cardiac failure explaining the respiratory failure. We reported patients ‘characteristics and latency periods. No nominative, sensitive or personal data of patients have been collected. Our study involved the reuse of already recorded and anonymized data. The study falls within the scope of the French Reference Methodology MR-004, which require neither information nor consent of the included individuals. Results are presented in mean ± SD. We studied 191 patients of 64.8 ± 10.4 years old, mostly male (64.9%), with PaO2/FiO2 of 141 ± 57 mm Hg, treated with neuromuscular blockers (98.2%) and prone position (90.9%), and having in ICU mortality of 20.9%. The mean times from symptoms onset to hospitalization, ICU admission and initiation of the mechanical ventilation were, respectively, 7.5 ± 3.3, 8.8 ± 3.3, and 10.5 ± 4.0 days (Fig. 1). Only 21.9% (42/191) of these critically ill and ventilated patients had respiratory failure developed within 1 week of the clinical onset and could actually be classified as ARDS according to the Berlin definition. Fig. 1 Latency periods between symptom onset and respiratory failure of critically ill COVID-19 patients requiring invasive mechanical ventilation. Patients received invasive mechanical ventilation with PaO2/FiO2 of 300 mm Hg or less, with bilateral infiltrates on chest imaging and without cardiac failure explaining the respiratory failure. Times from symptom onsets to hospitalization, ICU admission, and initiation of invasive mechanical ventilation are represented by dots (individual value) or black lines (mean value). The 1-week limit for the latency period of the Berlin definition of ARDS is represented by the red line In our experience, the large majority of ventilated COVID-19 patients failed to meet the criteria for the Berlin definition of ARDS, despite severe lung injury and live-threatening condition. Critically ill patients due to SARS-CoV-2 infection cannot be classified as sepsis [3] or as ARDS. The purpose of these observations is not to be picky with the definitions, but to highlight that COVID-19 has been a game changer in our ability to stratify the patients. Definition need to evolve as new information and experience is gained [4]. Considering an expanded definition of ARDS due to the COVID-19 pandemic is a legitimate question that should be considered. Modifying the latency period for the inciting clinical disorder should be included in this discussion. Given the slower progression of respiratory failure in COVID-19 compared with other causes of ARDS, we propose that a revised definition of ARDS could consider latency longer than 7 days from identification of the ARDS risk factor. As already suggested [4] and in agreement with our results, a latency period (between symptom onset and respiratory failure) up to 14 days seems to be optimal to define COVID-19 ARDS. Whether this longer latency period may apply to all respiratory viral infections including influenza is a more complicated question. In our experience, the time between the onset of symptoms and hospitalization is inferior to one week for viral pneumonia (non-COVID-19; unpublished data from [5]). In conclusion, we observed that the long latency period between symptom onset and respiratory failure preclude ventilated COVID-19 patients to be stratified as ARDS. We proposed to expand the latency period (up to 14 days) and welcome the feed-back of clinicians caring for critically ill COVID-19 patients.

          Related collections

          Most cited references5

          • Record: found
          • Abstract: found
          • Article: not found

          Acute respiratory distress syndrome: the Berlin Definition.

          The acute respiratory distress syndrome (ARDS) was defined in 1994 by the American-European Consensus Conference (AECC); since then, issues regarding the reliability and validity of this definition have emerged. Using a consensus process, a panel of experts convened in 2011 (an initiative of the European Society of Intensive Care Medicine endorsed by the American Thoracic Society and the Society of Critical Care Medicine) developed the Berlin Definition, focusing on feasibility, reliability, validity, and objective evaluation of its performance. A draft definition proposed 3 mutually exclusive categories of ARDS based on degree of hypoxemia: mild (200 mm Hg < PaO2/FIO2 ≤ 300 mm Hg), moderate (100 mm Hg < PaO2/FIO2 ≤ 200 mm Hg), and severe (PaO2/FIO2 ≤ 100 mm Hg) and 4 ancillary variables for severe ARDS: radiographic severity, respiratory system compliance (≤40 mL/cm H2O), positive end-expiratory pressure (≥10 cm H2O), and corrected expired volume per minute (≥10 L/min). The draft Berlin Definition was empirically evaluated using patient-level meta-analysis of 4188 patients with ARDS from 4 multicenter clinical data sets and 269 patients with ARDS from 3 single-center data sets containing physiologic information. The 4 ancillary variables did not contribute to the predictive validity of severe ARDS for mortality and were removed from the definition. Using the Berlin Definition, stages of mild, moderate, and severe ARDS were associated with increased mortality (27%; 95% CI, 24%-30%; 32%; 95% CI, 29%-34%; and 45%; 95% CI, 42%-48%, respectively; P < .001) and increased median duration of mechanical ventilation in survivors (5 days; interquartile [IQR], 2-11; 7 days; IQR, 4-14; and 9 days; IQR, 5-17, respectively; P < .001). Compared with the AECC definition, the final Berlin Definition had better predictive validity for mortality, with an area under the receiver operating curve of 0.577 (95% CI, 0.561-0.593) vs 0.536 (95% CI, 0.520-0.553; P < .001). This updated and revised Berlin Definition for ARDS addresses a number of the limitations of the AECC definition. The approach of combining consensus discussions with empirical evaluation may serve as a model to create more accurate, evidence-based, critical illness syndrome definitions and to better inform clinical care, research, and health services planning.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Diffuse alveolar damage--the role of oxygen, shock, and related factors. A review.

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The Berlin definition of acute respiratory distress syndrome: should patients receiving high-flow nasal oxygen be included?

              The 2012 Berlin definition of acute respiratory distress syndrome (ARDS) provided validated support for three levels of initial arterial hypoxaemia that correlated with mortality in patients receiving ventilatory support. Since 2015, high-flow nasal oxygen (HFNO) has become widely used as an effective therapeutic support for acute respiratory failure, most recently in patients with severe COVID-19. We propose that the Berlin definition of ARDS be broadened to include patients treated with HFNO of at least 30 L/min who fulfil the other criteria for the Berlin definition of ARDS. An expanded definition would make the diagnosis of ARDS more widely applicable, allowing patients at an earlier stage of the syndrome to be recognised, independent of the need for endotracheal intubation or positive-pressure ventilation, with benefits for the testing of early interventions and the study of factors associated with the course of ARDS. We identify key questions that could be addressed in refining an expanded definition of ARDS, the implementation of which could lead to improvements in clinical practice and clinical outcomes for patients.
                Bookmark

                Author and article information

                Contributors
                antoine.guillon@univ-tours.fr
                Journal
                Infection
                Infection
                Infection
                Springer Berlin Heidelberg (Berlin/Heidelberg )
                0300-8126
                1439-0973
                14 September 2021
                : 1-2
                Affiliations
                [1 ]GRID grid.411167.4, ISNI 0000 0004 1765 1600, Intensive Care Unit, , Tours University Hospital, ; 2 Bd Tonnellé, 37044 Tours Cedex 9, France
                [2 ]GRID grid.12366.30, ISNI 0000 0001 2182 6141, University of Tours, ; Tours, France
                [3 ]Research Center for Respiratory Diseases, INSERM U1100, Tours, France
                Author information
                http://orcid.org/0000-0002-4884-8620
                Article
                1694
                10.1007/s15010-021-01694-7
                8439365
                93422566-e469-4345-b056-ff0bcb8413dd
                © Springer-Verlag GmbH Germany, part of Springer Nature 2021

                This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.

                History
                : 7 July 2021
                : 1 September 2021
                Categories
                Correspondence

                Infectious disease & Microbiology
                Infectious disease & Microbiology

                Comments

                Comment on this article